Category Archive: NYSE:MRK

Pharma Failures Actually Advance Medicine

The fact is we want big pharma to work on these difficult challenges. No other entity can do this.

Biopharma Attacked For Excessive Profits On Drugs For Children

These laws have transformed the way medicines are developed for pediatric populations.

Harvard Professor’s Attack On Pharma’s Clinical Trials Is Absurd

Yes, we must be vigilant to be certain that studies are run ethically and that results are published accurately and on time. But, to say that academic-industry relationships are full of “corruption” is both wrong and irresponsible.

FDA’s New Generic EpiPen Approval Exemplifies Progress on Drug Price Reform

Last week, FDA Commissioner Scott Gottlieb announced the approval of the first generic version of EpiPen, an injectable form of epinephrine used in children to treat life-threatening allergies. Under Gottlieb and HHS Secretary Alex Azar, the consistent…

Theranos? Whatever. Healthcare Startups Have Raised $15 Billion So Far This Year

The total number of companies splitting that cash pile has dropped, from 855 in the first six months of 2017 to 779 in the first half of 2018, meaning investors have chosen to make bigger bets in a smaller number of companies.

Summer Fun – Infections From Animals

Animal related infections are the major source of human infections as well. As we increase our exposure to nature, here are a few zoonotic infections to be aware of.

The Biopharmaceutical Industry Provides 75% Of The FDA’s Drug Review Budget. Is This A Problem?

If you were to ask the CEOs of Pfizer, Merck, Lilly, etc., they would be more than happy to drop the “user fees” and have Congress fully fund the FDA via other funding mechanisms.

Big Pharma Rises To The Ebola Challenge

“If you have technology that can help fight the most deadly virus in the world, you can’t stand back and not do this.”

Explore the Archive